# Increase of CXCR3 $^{\dagger}$ T cells impairs Th17 cells recruitment in the small intestine mucosa through IFN- $\gamma$ and IL-18 during treated HIV-1 infection

C Loiseau<sup>1,2\*</sup>, M Requena<sup>3</sup>, M Nayrac<sup>1</sup>, M Mavigner<sup>4</sup>, M Cazabat<sup>3</sup>, AL Iscache<sup>1</sup>, N Carrere<sup>5,6</sup>, B Suc<sup>5,6</sup>, L Alric<sup>5,7,8</sup>, J Izopet<sup>1,3,5</sup> and P Delobel<sup>1,5,9</sup>

<sup>1</sup>INSERM, UMR1043, Toulouse, F-31300 France

<sup>2</sup>Centre for Molecular Therapeutics, Australian Institute of Tropical Health & Medicine, James Cook University, Cairns, QLD 4870, Australia

<sup>3</sup>CHU de Toulouse, Laboratoire de Virologie, Toulouse, F-31300 France

<sup>4</sup>Department of Pediatrics and Center for AIDS Research, Emory University School of Medicine, Atlanta, GA 30329 United States of America

<sup>5</sup>Université Toulouse III Paul Sabatier, Toulouse, F-31300 France

<sup>6</sup>CHU de Toulouse, Service de Chirurgie générale et digestive, Toulouse, F-31300 France

<sup>7</sup>CHU de Toulouse, Service de Médecine Interne, Toulouse, F-31300 France

<sup>8</sup>IRD UMR152, Toulouse, F-31400 France.

<sup>9</sup>CHU de Toulouse, Service des Maladies Infectieuses et Tropicales, Toulouse, F-31300 France

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

\*Current affiliation

The authors have declared that no conflict of interest exists.

Correspondence should be addressed to: P. Delobel, INSERM, UMR1043, Toulouse, F-31300 France.

Tel: +33 5 61 77 75 08; fax: +33 5 61 77 21 38; e-mail: delobel.p@chu-toulouse.fr

Financial support: French National Agency for Research on AIDS and Viral Hepatitis; Sidaction

# **Summary:**

Increase in Th1-type cells in the duodenal mucosa of HIV-1-infected individuals under antiretroviral therapy could contribute to a reduction of CCL20 and CCL25 expression by enterocytes through IL-18 and IFN- $\gamma$ , while inducing CXCR3-ligands, thus perpetuating Th17/Th1 imbalance.

**Abstract** 

The restoration of CD4<sup>+</sup> T cells, especially of Th17 cells, remains incomplete in the gut mucosa of

most HIV-1-infected individuals despite sustained antiretroviral therapy (ART). Herein, we report an

increase in absolute number of CXCR3<sup>+</sup> T cells in the duodenal mucosa on ART. The frequencies of

Th1 and CXCR3<sup>+</sup> CD8<sup>+</sup> T cells were increased and negatively correlated with CCL20 and CCL25

expression in the mucosa. Ex-vivo, we showed that IFN-γ, the main cytokine produced by Th1 and

effector CD8<sup>+</sup> T cells, down-regulates the expression of CCL20 and CCL25 by small intestine

enterocytes, while it increases the expression of CXCL9/10/11, the ligands of CXCR3. IL-18, a pro-Th1

cytokine produced by enterocytes also contributes to down-regulate CCL20 expression, and

increases IFN-γ production by Th1 cells. This could perpetuate an amplification loop for CXCR3-

driven Th1-type cells recruitment to the gut, while impairing Th17 cells homing through the CCR6-

CCL20 axis in treated HIV-1-infected individuals.

Key words: HIV-1; gut; CXCR3; Th1; CD8; IFN-γ; IL-18; CCL20; CCL25

3

#### **INTRODUCTION**

During HIV-1 infection, the integrity of the intestinal immune barrier is disrupted due to a deep depletion of gut CD4<sup>+</sup> T cells [1, 2]. Among them, Th17 cells, which have a major role in antimicrobial mucosal immunity, are particularly targeted [3]. Th17 cell loss has been linked to microbial translocation from the gut lumen into the bloodstream, resulting in deleterious systemic inflammation [4, 5].

Despite a prolonged and effective antiretroviral therapy (ART), the restoration of CD4<sup>+</sup> T cells remains incomplete in the gut mucosa (particularly in effector sites, *i.e. lamina propria*) of most HIV-1-infected individuals. This contrasts with the significant restoration of CD4<sup>+</sup> T cells in their peripheral blood and organized lymphoid tissues [1, 6-8]. We previously reported that a lack of recruitment of CD4<sup>+</sup> T cells to the gut could contribute to this impaired immune reconstitution [9].

The  $\alpha4\beta7$ -MAdCAM-1, CCR9-CCL25, and CCR6-CCL20 chemotactic axes play critical roles in the homing of immune cells to the small intestine. The  $\alpha4\beta7$  integrin binds MAdCAM-1, which is expressed on gut endothelial cells [10]. CCL25 and CCL20 chemokines, which are produced by enterocytes, drive the homing of CCR9- and CCR6-expressing immune cells, respectively [11-13].

We previously described alterations in the CCR9-CCL25 and CCR6-CCL20 chemotactic axes that could contribute to the poor restoration of CD4<sup>+</sup> T cell in the small intestine mucosa of treated HIV-1-infected individuals who initiated ART during the chronic phase of infection [9, 14]. This appears to be linked to a reduced production of both CCL20 and CCL25 by small intestine enterocytes. CCL20 down-regulation specifically impacts the mucosal recruitment of CCR6<sup>+</sup> CD4<sup>+</sup> T cells, notably Th17 cells [14].

We found that the frequency of Th1 and CD8<sup>+</sup> T cells is increased in the duodenal mucosa of HIV-1-infected individuals on ART, contrasting with the global depletion of gut CD4<sup>+</sup> T cells. Th1 and effector CD8<sup>+</sup> T cells share the expression of CXCR3, suggesting that the CXCR3 chemotactic axis

could be functional in this setting. We thus assessed whether CXCR3<sup>+</sup> T cells could play a role in the disequilibrium of the gut mucosa homeostasis observed in treated HIV-1-infected individuals. We examined the impact of Th1-type inflammation on the production of chemokines by the enterocytes and how it drives Th1 and Th17 cells recruitment to the gut mucosa.



#### **METHODS**

Individuals and samples. The ANRS EP44 study group was previously described [9]. Briefly, 20 HIV-1-infected individuals were studied. They received effective ART for a median of 5 years (IQR, [4–5.5]), initiated during the chronic stage of infection. All had sustained plasma HIV-1 RNA <20 copies/mL. Their median blood CD4<sup>+</sup> T cell count was 668 cells/μL (IQR [451–849]) on ART at the time of sampling. Patient demographic information is available in supplemental Table S1. Twenty uninfected individuals were used as controls. Biopsies of duodeno-jejunal mucosa and blood samples were collected from each patient. Additional information is available in supplemental methods.

**Ethics statement.** The study was approved by the Institutional Review Board CPP Sud-Ouest et Outre-Mer II. All participants provided informed consent (trial registration number NCT01038401).

Isolation and phenotyping of small intestine mucosal lymphocytes. Duodeno-jejunal biopsies (n=5) were digested with 0.5 mg/mL collagenase type II-S (Sigma-Aldrich). T cells were isolated by positive selection (EasySep Human CD3-Positive Selection Kit, Stemcell). Flow cytometry analyses were performed on a BD LSRFortessa (BD Biosciences). Th1 and Th17 cells were defined as CD3<sup>+</sup>CD4<sup>+</sup>CXCR3<sup>+</sup>CCR4<sup>-</sup>CCR6<sup>-</sup>, and CD3<sup>+</sup>CD4<sup>+</sup>CXCR3<sup>-</sup>CCR4<sup>+</sup>CCR6<sup>+</sup>CD161<sup>+</sup> cells, respectively. CD8<sup>+</sup> T cells were defined as CD3<sup>+</sup>CD4<sup>-</sup>CD8<sup>+</sup> cells. Additional information is available in supplemental methods.

Immunohistochemistry. Fresh tissues were fixed in 4% neutral buffered formalin and embedded in paraffin. Immunohistochemistry was performed on 3  $\mu$ m sections using anti-CXCR3 (R&D Systems) mAb. Quantification was performed using LAS v3.7 (Leica microsystems) and NIS-element (Nikon), in a blinded fashion regarding HIV-1 infection status.

Isolation, culture, and differentiation of primary small intestine epithelial cells (IEC). IEC were isolated from upper small bowel surgical resections obtained from individuals free of HIV and inflammatory bowel diseases. Subsequent culture and enterocytes differentiation were performed as described in supplemental methods.

*Ex-vivo* stimulation of primary IEC by cytokines. Primary IEC cultured on transwell inserts were stimulated for 15 hours with 0.5, 5, or 50 ng/mL of human IFN- $\gamma$ , IL-2, TNF- $\alpha$ , IL-18 (ThermoFisher), IL-17A, IL-1ß (eBiosciences) added into the bottom chamber.

Th1 and Th17 cell sorting and coculture with primary IEC. Th1 and Th17 cells were sorted by flow cytometry on a FACSARIA II (BD Biosciences) from PBMCs of healthy donors. Gating strategy is shown in supplemental Figure S1. Sorted Th1 and Th17 cells were cultured in CTS OpTmizer medium (Life Technologies) and activated with PMA/ionomycin before being added into the bottom chamber for coculture with IEC on transwell inserts during 15 hours. Anti-IFN- $\gamma$ R1 mAb (10  $\mu$ g/mL, Universal Biologicals) and IL-18BP (1  $\mu$ g/mL, R&D systems) were used to antagonize the biological effect of IFN- $\gamma$  or IL-18, respectively. Additional information is available in supplemental methods.

RT-PCR quantification of chemokine mRNAs. RNA was extracted from primary IEC using the RNeasy minikit (Qiagen). CCL20 and CCL25 mRNA quantification was performed on a LightCycler 480 (Roche). CXCL9, CXCL10, CXCL11, pro-IL-18, IL-18RAP, IL-18BP, and Caspase-1 mRNAs were quantified with the QuantiGene-Plex 2.0 Assay (Affymetrix). Additional information is available in supplemental methods.

**Quantification of chemokines.** CCL20, CXCL9, CXCL10, and CXCL11 were quantified by ELISA (R&D Systems) in the bottom chamber of transwells.

Cell migration assay. Sorted Th1 or Th17 cells were loaded in the upper chamber and control medium or conditioned medium from Th1:IEC or Th17:IEC cocultures was loaded in the bottom chamber of transwells (Corning). The number of cells trafficking from the upper to the bottom chamber through the 5  $\mu$ m-pore membrane in 15 hours was counted. Anti-CCL20 mAb, and a mix of anti-CXCL9/10/11 Abs was used to antagonize chemotaxis. Additional information is available in supplemental methods.

**Statistical analyses.** Quantitative variables were compared using the Wilcoxon's rank-sum test. Paired Wilcoxon's test was used to compare chemokine expression between the different conditions in IEC cultures from each donor. Correlations were estimated by calculating Spearman's rank correlation coefficients. All tests were 2-sided, and *P* values <0.05 were considered statistically significant. Statistical analyses were performed with Stata 10.0.

#### **RESULTS**

Increase of CXCR3<sup>+</sup> T cells in the duodenal mucosa of treated HIV-1-infected individuals suggests effective cell recruitment through this axis.

We and others previously showed that the frequency and absolute number of CD4 $^{+}$  T cells in the *lamina propria* of the intestine mucosa of HIV-1-infected individuals do not normalize, despite sustained effective ART [1, 6-9]. However, the restoration is not uniform among different CD4 $^{+}$  T cell subsets. In contrast to gut Th17 cells, whose frequency remained lower in the duodenal mucosa of treated HIV-1-infected individuals than in uninfected controls (median frequency of 4.3% vs. 7.6%, respectively, P=0.031), we found that the frequency of gut Th1 in CD4 $^{+}$  T cells was increased in treated HIV-1-infected individuals compared to uninfected controls (median frequency of 9.0% vs. 4.7%, respectively, P=0.001; Figure 1A).

The increased frequency of Th1 cells suggests effective recruitment of this cell subset to the gut mucosa. Th1 are characterized by the expression of CXCR3, a chemokine receptor involved in T cell trafficking to peripheral sites of Th1-type inflammation. Effector CD8<sup>+</sup> T cells share expression of CXCR3 with Th1 cells. Similarly, the frequency of CXCR3<sup>+</sup> in CD8<sup>+</sup> T cells was increased (median frequency of 27.4% vs. 18.1%, *P*=0.012, Figure 1B) in the duodenal mucosa of treated HIV-1-infected individuals compared to uninfected controls.

Flow cytometry data were confirmed by *in-situ* detection of CXCR3<sup>+</sup> cells, the absolute number of CXCR3<sup>+</sup> cells was increased in treated HIV-1-infected individuals compared to uninfected controls (quantification of CXCR3<sup>+</sup> cells per unit surface area, *P*=0.020; Figure 1C). Immunochemistry analysis showed that CXCR3<sup>+</sup> cells were mainly localized in the *lamina propria* of the duodenal mucosa (Figure 1D).

This suggests that CXCR3-mediated cell recruitment, involved in the homing of Th1 and effector CD8<sup>+</sup>

T cells to the gut, is functional in this setting.

*In-vivo*, the frequencies of Th1 and CXCR3<sup>+</sup> in CD8<sup>+</sup> T cells negatively correlate with CCL20 and CCL25 expression in the duodenal mucosa.

We previously linked the lack of immune reconstitution of gut CD4 $^{\circ}$  T cells, notably of CCR6 $^{\circ}$  cells such as Th17 cells, to a decreased expression of CCL20 and CCL25 in the duodenal enterocytes of treated HIV-1-infected individuals [9, 14]. However, the factors influencing CCL20 and CCL25 expression in HIV-1-infected individuals remain unclear. Herein, we found that the frequency of gut Th1 cells was negatively correlated with the expression of CCL20 ( $\rho$ =-0.51, P=0.007, Figure 2A) and CCL25 ( $\rho$ =-0.81, P<0.0001, Figure 2B) in the duodenal mucosa. Similarly, the frequency of gut CXCR3 $^{\circ}$  in CD8 $^{\circ}$  T cells was negatively correlated with the expression of CCL20 ( $\rho$ =-0.47,  $\rho$ =0.013, Figure 2C) and CCL25 ( $\rho$ =-0.48,  $\rho$ =0.043, Figure 2D). It should be noted that these correlations were statistically non-significant when analyzed separately in HIV-1 infected individuals and uninfected controls. However, the frequency of total duodenal CD8 $^{\circ}$  T cells (most of which were effector memory cells, data not shown) of HIV-1-infected individuals, with an increased subject number, was also negatively correlated with the expression of CCL20 ( $\rho$ =-0.55,  $\rho$ =0.022) and CCL25 ( $\rho$ =-0.53,  $\rho$ =0.024, supplemental Figure S2).

These findings prompted us to investigate whether Th1 and effector CD8<sup>+</sup> T cells could play a functional role in reducing the expression of CCL20 and CCL25 chemokines by enterocytes.

# Ex-vivo, IFN-γ blunts CCL20 and CCL25 expression by enterocytes.

The functional impact of IFN-γ, the main cytokine produced by Th1 and effector CD8<sup>+</sup> T cells, on enterocyte chemokine expression was investigated using an *ex-vivo* model of human primary IEC

isolated from the upper small intestine and cultured as monolayers of differentiated enterocytes on transwell inserts. To mimic the epithelium-*lamina propria* interaction, the enterocytes were stimulated at their basal side by cytokines. mRNA expression was quantified by qRT-PCR in the enterocytes.

The quantification of CCL20 and CCL25 mRNA revealed that IFN- $\gamma$  induced a decreased expression of both chemokines by enterocytes, with a stronger effect on CCL20 expression (up to 6-fold decrease, P=0.005) than on CCL25 (up to 3-fold decrease, P=0.002) (Figure 3A, left panel).

In addition to IFN- $\gamma$ , poly-functional Th1 and effector CD8<sup>+</sup> T cells can also produce IL-2 and TNF- $\alpha$ . We thus assessed the impact of these cytokines on enterocyte expression of CCL20 and CCL25. IL-2 slightly decreased CCL20 expression (up to 2-fold decrease, P=0.027) while it had no consistent effect on CCL25 expression (Figure 3A, center panel). By contrast, TNF- $\alpha$  importantly increased CCL20 expression (up to 3-log increase, P=0.001) while it reduced CCL25 expression (up to 3-fold decrease, P=0.001) (Figure 3A, right panel).

IL-17A, the main Th17 cytokine, moderately increased CCL20 expression (up to 3-fold, *P*=0.002), while it had no consistent effect on CCL25 expression (Figure 3B).

# Ex-vivo, IL-18 and IL-1ß had opposite effects on CCL20 and CCL25 expression by enterocytes.

IL-18 is a pro-Th1 cytokine which is released by the enterocytes through activation of the epithelial inflammasome [15]. As IFN- $\gamma$ , IL-18 induced a marked decrease of CCL20 expression (up to 6-fold decrease, P=0.008), and a non-significant increase of CCL25 expression (less than 2-fold increase, P=0.26) (Figure 3C, left panel).

IL-1ß, a pro-Th17 cytokine, is produced, as IL-18, through activation of the inflammasome. However, contrary to IL-18, the enterocytes are not a significant source of IL-1ß which is mainly produced by

gut macrophages in inflammatory conditions [15]. IL-1 $\beta$  strongly induced CCL20 expression (more than 3-log increase, P=0.008) by enterocytes while it reduced CCL25 expression (up to 4-fold, P=0.008) (Figure 3C, right panel).

IL-18 and IL-1ß thus have strong opposite effects on CCL20 expression. Both are released upon activation of the inflammasome but producing cells and triggers are not the same in the intestine mucosa [15].

Herein, we found that IL-18 level was increased in the plasma of treated HIV-1-infected individuals compared to uninfected controls (*P*=0.033, supplemental Figure S3). By contrast, IL-1ß level was not different (*P*=0.67, supplemental Figure S3). Increased IL-18 level may thus contribute to a pro-Th1 environment in treated HIV-1-infected individuals.

Gene expression analyses were confirmed by the quantification of CCL20 protein by ELISA (Figure 3D). CCL25 protein could not be quantified as the levels produced *ex-vivo* were below the detection limit.

Interactions between Th1 cells and enterocytes blunt CCL20 and CCL25 expression through IL-18 and IFN- $\gamma$ .

To mimic the epithelium-*lamina propria* interactions in a Th1- or Th17-microenvironment and, to globally assess the combined effect of cytokines, the primary IEC were co-cultured with Th1 or Th17 cells added into the bottom chamber of transwells. mRNA expression was quantified by qRT-PCR in the enterocytes. We found that a Th1-microenvironment lead to a 5-fold decrease in CCL20 (*P*=0.017) and a 2-fold decrease in CCL25 expression (*P*=0.041, Figure 4A) by the enterocytes relatively to a Th17-microenvironment. These results were confirmed by ELISA with a 2-fold decrease of CCL20 protein in Th1:IEC compared to Th17:IEC cocultures (*P*=0.040, Figure 4B). CCL25 protein could not be quantified as the levels produced were below the detection limit.

The decrease of CCL25 expression in Th1:IEC coculture was mainly due to IFN- $\gamma$  as blocking IFN- $\gamma$  biological activity through IFN- $\gamma$ R1 significantly restored CCL25 expression (P=0.043, Figure 4C), while blocking IL-18 biological activity by IL-18BP did not have any significant impact. By contrast, blocking IFN- $\gamma$ R1 did not change CCL20 expression, while it was restored when blocking IL-18 (P=0.025, Figure 4D).

These results suggest that IFN- $\gamma$  and IL-18 cooperate in reducing CCL20 and CCL25 expression by enterocytes in a Th1-microenvironment compared to a Th17-microenvironment.

# IFN-γ and IL-18 synergize to amplify the Th1 response in the gut mucosa.

Stimulation of the enterocytes by IFN- $\gamma$  increased their expression of pro-IL-18 mRNA (up to 3-log increase, P=0.011, Figure 5A). It also increased the expression of the IL-18 receptor accessory protein (IL-18RAP) (more than 2-log increase, P=0.021, Figure 5B). IL-18RAP has been shown to increase IL-18 binding and signaling [18]. But IFN- $\gamma$  also induced the expression of the IL-18 antagonist IL-18BP by enterocytes (data not shown), allowing for tight regulation of the IL-18 biological effect in the gut mucosa.

Production of mature IL-18 by the enterocytes requests activation of the epithelial inflammasome, leading to the cleavage of pro-IL-18 into mature IL-18 by caspase-1 [15]. In coculture experiments, caspase-1 expression was increased by 2-fold in Th1:IEC but not in Th17:IEC cocultures (*P*=0.011, Figure 5C).

IL-18 production by the enterocytes amplified IFN- $\gamma$  production by Th1 cells as IFN- $\gamma$  production was 4-fold increased if Th1 cells were cultured in presence of IL-18 (P= 0.006, Figure 5D).

These results suggest that a pro-Th1 amplification loop could occur between IFN- $\gamma$ , produced by Th1 cells, and IL-18, produced by the enterocytes, in the intestinal mucosa.

## Ex-vivo, IFN-y increases CXCR3 ligands expression by enterocytes.

We found increased frequencies of CXCR3<sup>+</sup> T cells, notably Th1 and effector CD8<sup>+</sup> T cells, in the duodenal mucosa of treated HIV-1-infected individuals compared to uninfected controls. The recruitment of CXCR3<sup>+</sup> T cells to the gut mainly depends on the production of CXCR3-ligands CXCL9, CXCL10, and CXCL11. Quantification of CXCL9, CXCL10, and CXCL11 mRNA in primary IEC stimulated with IFN-γ demonstrated a highly-upregulated expression (up to 5-log increase) for the three chemokines, albeit less pronounced for CXCL11 (*P*=0.008, Figure 6A, left panel). It should be noted that basal CXCL11 expression by enterocytes in unstimulated conditions was much higher (16- to 64-fold) than CXCL9 and CXCL10 expression, both of which rather appeared to be highly inducible (data not shown). Gene expression analyses were confirmed by the quantification of CXCL9, CXCL10, and CXCL11 proteins by ELISA (*P*=0.028 for CXCL9 and CXCL10, Figure 6A, right panel).

IL-18 had no impact on CXCL9, CXCL10, and CXCL11 expression by enterocytes at mRNA and protein levels (data not shown), by opposition to its effect on CCL20 expression.

These results were confirmed by comparing Th1:IEC vs. Th17:IEC cocultures; a 10- to 40-fold increase in CXCL9, CXCL10, and CXCL11 expression was observed in a Th1-microenvironment relatively to a Th17-microenvironment (P=0.008, Figure 6C). These results were confirmed by ELISA with an increase production of CXCL9 (P=0.007) and CXCL10 (P=0.013) chemokines in Th1:IEC compared to Th17:IEC cocultures (Figure 6C). This effect is mainly driven by IFN- $\gamma$  as blocking its biological activity through IFN- $\gamma$ R1 significantly reduced CXCL9, CXCL10, and CXCL11 expression (P=0.008, Figure 6D).

# Interactions between Th1 cells and enterocytes amplify the recruitment of Th1 over Th17 cells.

Finally, we assessed the global effect of the interactions between Th1 cells and enterocytes on the recruitment of Th1 and Th17 cells. We performed cell migration assay using conditioned medium from Th1:IEC or Th17:IEC cocultures to assess chemotaxis of Th1 and Th17 cells. Conditioned medium from Th1:IEC coculture induced the recruitment of twice more Th1 than Th17 cells, and this effect was dependent on CXCR3 ligands as blocking CXCL9, CXCL10, and CXCL11 chemokines blunted Th1 cells recruitment (*P*=0.023, Figure 7A). Conversely, Th17 cells recruitment mainly depended on CCL20 and is favored over Th1 cells by a Th17 microenvironment (*P*=0.038, Figure 7B).

Taken together, these data suggest that a gut microenvironment enriched with IFN- $\gamma$ -producing CXCR3<sup>+</sup> cells, such as Th1 and effector CD8<sup>+</sup> T cells, stimulates the expression of CXCR3-ligands CXCL9, CXCL10, and CXCL11 in response to IFN- $\gamma$ , but decreases the expression of CCL20 and CCL25 through IFN- $\gamma$  and IL-18. This perpetuates a pro-Th1 amplification loop for cell recruitment to the gut at the expense of other CD4<sup>+</sup> T cell subsets, notably Th17 cells that mainly depend on the CCR6-CCL20 axis.

#### **DISCUSSION**

Herein, we showed that the frequencies of Th1 and CXCR3<sup>+</sup> CD8<sup>+</sup> T cells are increased in the duodenal mucosa of HIV-1-infected individuals on ART, contrasting with the impaired homing of CCR6<sup>+</sup> CD4<sup>+</sup> T cells, including Th17 cells [14]. Th1 and effector CD8<sup>+</sup> T cells share the expression of CXCR3, suggesting efficient homing through this chemotactic axis in this setting, while the CCR6-CCL20 and CCR9-CCL25 axes appear to be impaired, as previously shown [9, 14].

Our results also suggest a functional role of Th1 and effector CD8<sup>+</sup> T cells, mediated by IFN- $\gamma$  and IL-18, in the down-regulation of CCL20 and CCL25 expression by enterocytes. By contrast, IFN- $\gamma$  strongly increases the expression of CXCR3 ligands, creating an amplification loop that promotes Th1-type cells recruitment to sites of inflammation, in agreement with previous reports [19, 20]. In addition to CD4<sup>+</sup> and CD8<sup>+</sup> T cells, the recruitment of CXCR3<sup>+</sup> cells in the gut mucosa could also concern ILC1, NK, and NKT cells, that share IFN- $\gamma$  production [21].

CCL20 is usually considered as an inducible inflammatory chemokine, with increased expression reported in inflammatory bowel diseases and some enteric infections [22], contrasting with an increase of CXCR3 ligands in some other infections [23]. Thus, the pathways involved in mucosal immune responses differ between the various settings, favouring either Th17 or Th1 responses. *Invivo*, we reported that treated HIV-1-infection was associated with a reduced expression of CCL20 by small intestine enterocytes [14]. *Ex-vivo*, the regulatory T cell (Treg) cytokines TGF- $\beta$  and IL-10, and the Th1 cytokine IFN- $\gamma$  down-regulate CCL20 expression, while the Th17 cytokine IL-17A increases it [14]. The down-regulated expression of CCL20 thus matches with the imbalance in the Th17/Treg and Th17/Th1 ratios that we observed in the duodenal mucosa of treated HIV-1-infected individuals. The inflammasome cytokines IL-18 and IL-1 $\beta$  have strong opposite effects on CCL20 expression by enterocytes. IL-18, which is a pro-Th1 cytokine produced by enterocytes, decreases CCL20

expression, while IL-1 $\beta$ , a pro-Th17 cytokine produced by inflammatory macrophages in the gut mucosa increases CCL20 expression. IFN- $\gamma$  and IL-18 thus appear to cooperate in reducing CCL20 expression and creating an amplification loop for Th1-type cells recruitment.

The nature of the inflammatory stimuli that could drive Th1-type inflammation in the gut mucosa of treated HIV-1-infected individuals remains unclear. HIV-1 DNA persists at higher levels in gut than in blood CD4<sup>+</sup> T cells, and HIV-1 RNA can be detected in the gut mucosa despite sustained effective ART [9, 24]. Residual HIV-1 RNA could be due to low-level virus replication that continues despite ART and/or the sporadic release of viruses from latently infected cells when being activated. Even low-level production of virus particles or proteins could provide enough antigenic stimuli for driving HIV-specific T cell responses.

Mucosal reactivation of CMV in the gut could also be an important driver of T cell activation [25, 26]. Repeated microbial translocation events, through breaches of the gut epithelium, could also provide inflammatory stimuli driving the recruitment of effector immune cells to the gut mucosa [27]. The inflammasome IL-1 $\beta$  and IL-18 cytokines could play an important role in orientating the mucosal immune response [28-30]. IL-18 seems predominant in the setting of HIV-1 infection [16, 17]. We found increased plasma levels of IL-18, but not of IL-1 $\beta$ , in the treated HIV-1-infected individuals included in the present study.

In conclusion, we have found increased frequencies of Th1 in CD4<sup>+</sup> and CXCR3<sup>+</sup> in CD8<sup>+</sup> T cells in the duodenal mucosa of HIV-1-infected individuals on ART, in contrast with the reduced frequency of Th17 cells. Absolute numbers of mucosal CXCR3<sup>+</sup> cells were increased, suggesting efficient cell recruitment through this chemotactic axis in this setting. We showed that the interactions between Th1 and enterocytes lead to a decrease in CCL20 and CCL25 expression but to an increase in CXCR3-ligands production by enterocytes, creating a positive feedback loop for Th1-type cells recruitment to the gut, while impairing Th17 cells homing through the CCR6-CCL20 axis.

## **ACKNOWLEDGMENTS**

This project was supported by grants from the French National Agency for Research on AIDS and Viral Hepatitis and Sidaction. We are indebted to the patients who took part in this study. We also thank V. Duplan-Eche and F.-E. L'Faqihi for their help in flow cytometry cell sorting; F. Capilla, C. Salon, and T. Alsaati for their help in immunohistochemistry; and Martha M. Cooper for checking the English text.

#### REFERENCES

- 1. Guadalupe M, Reay E, Sankaran S, et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol **2003**; 77:11708-17.
- 2. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med **2004**; 200:749-59.
- 3. Favre D, Lederer S, Kanwar B, et al. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog **2009**; 5:e1000295.
- 4. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med **2006**; 12:1365-71.
- 5. Kim CJ, McKinnon LR, Kovacs C, et al. Mucosal Th17 cell function is altered during HIV infection and is an independent predictor of systemic immune activation. J Immunol **2013**; 191:2164-73.
- 6. Guadalupe M, Sankaran S, George MD, et al. Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J Virol **2006**; 80:8236-47.
- 7. Mehandru S, Poles MA, Tenner-Racz K, et al. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med **2006**; 3:e484.
- 8. Kok A, Hocqueloux L, Hocini H, et al. Early initiation of combined antiretroviral therapy preserves immune function in the gut of HIV-infected patients. Mucosal Immunol **2015**; 8:127-40.
- 9. Mavigner M, Cazabat M, Dubois M, et al. Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. J Clin Invest **2012**; 122:62-9.
- 10. Streeter PR, Berg EL, Rouse BT, Bargatze RF, Butcher EC. A tissue-specific endothelial cell molecule involved in lymphocyte homing. Nature **1988**; 331:41-6.
- 11. Kunkel EJ, Campbell JJ, Haraldsen G, et al. Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity. J Exp Med **2000**; 192:761-8.
- 12. Iwasaki A, Kelsall BL. Localization of distinct Peyer's patch dendritic cell subsets and their recruitment by chemokines macrophage inflammatory protein (MIP)-3alpha, MIP-3beta, and secondary lymphoid organ chemokine. J Exp Med **2000**; 191:1381-94.
- 13. Cook DN, Prosser DM, Forster R, et al. CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity **2000**; 12:495-503.
- 14. Loiseau C, Requena M, Mavigner M, et al. CCR6(-) regulatory T cells blunt the restoration of gut Th17 cells along the CCR6-CCL20 axis in treated HIV-1-infected individuals. Mucosal Immunol **2016**; 9:1137-50.

- 15. Man SM. Inflammasomes in the gastrointestinal tract: infection, cancer and gut microbiota homeostasis. Nat Rev Gastroenterol Hepatol **2018**; 15:721-37.
- 16. Allam O, Samarani S, Mehraj V, et al. HIV induces production of IL-18 from intestinal epithelial cells that increases intestinal permeability and microbial translocation. PLoS One **2018**; 13:e0194185.
- 17. Samarani S, Allam O, Sagala P, et al. Imbalanced production of IL-18 and its antagonist in human diseases, and its implications for HIV-1 infection. Cytokine **2016**; 82:38-51.
- 18. Cheung H, Chen NJ, Cao Z, Ono N, Ohashi PS, Yeh WC. Accessory protein-like is essential for IL-18-mediated signaling. J Immunol **2005**; 174:5351-7.
- 19. Dwinell MB, Lugering N, Eckmann L, Kagnoff MF. Regulated production of interferon-inducible T-cell chemoattractants by human intestinal epithelial cells. Gastroenterology **2001**; 120:49-59.
- 20. Shibahara T, Wilcox JN, Couse T, Madara JL. Characterization of epithelial chemoattractants for human intestinal intraepithelial lymphocytes. Gastroenterology **2001**; 120:60-70.
- 21. Groom JR, Luster AD. CXCR3 in T cell function. Exp Cell Res 2011; 317:620-31.
- 22. Lee AY, Eri R, Lyons AB, Grimm MC, Korner H. CC Chemokine Ligand 20 and Its Cognate Receptor CCR6 in Mucosal T Cell Immunology and Inflammatory Bowel Disease: Odd Couple or Axis of Evil? Front Immunol **2013**; 4:194.
- 23. Sperandio B, Regnault B, Guo J, et al. Virulent Shigella flexneri subverts the host innate immune response through manipulation of antimicrobial peptide gene expression. J Exp Med **2008**; 205:1121-32.
- 24. Yukl SA, Shergill AK, Ho T, et al. The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence. J Infect Dis **2013**; 208:1212-20.
- 25. Gianella S, Chaillon A, Mutlu EA, et al. Effect of cytomegalovirus and Epstein-Barr virus replication on intestinal mucosal gene expression and microbiome composition of HIV-infected and uninfected individuals. AIDS **2017**; 31:2059-67.
- 26. Maidji E, Somsouk M, Rivera JM, Hunt PW, Stoddart CA. Replication of CMV in the gut of HIV-infected individuals and epithelial barrier dysfunction. PLoS Pathog **2017**; 13:e1006202.
- 27. Mudd JC, Brenchley JM. Gut Mucosal Barrier Dysfunction, Microbial Dysbiosis, and Their Role in HIV-1 Disease Progression. J Infect Dis **2016**; 214 Suppl 2:S58-66.
- 28. Coccia M, Harrison OJ, Schiering C, et al. IL-1beta mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells. J Exp Med **2012**; 209:1595-609.
- 29. Shaw MH, Kamada N, Kim YG, Nunez G. Microbiota-induced IL-1beta, but not IL-6, is critical for the development of steady-state TH17 cells in the intestine. J Exp Med **2012**; 209:251-8.

30. Harrison OJ, Srinivasan N, Pott J, et al. Epithelial-derived IL-18 regulates Th17 cell differentiation and Foxp3(+) Treg cell function in the intestine. Mucosal Immunol **2015**; 8:1226-36.



#### **FIGURE LEGENDS**

Figure 1. Increased frequency of Th1 in CD4<sup>+</sup> and CXCR3<sup>+</sup> in CD8<sup>+</sup> T cells contrasts with Th17 cells depletion in the duodenal mucosa of treated HIV-1-infected individuals.

**A.** Frequency of Th17 cells (CD3<sup>+</sup> CD4<sup>+</sup> CXCR3<sup>-</sup> CCR4<sup>+</sup> CCR6<sup>+</sup> CD161<sup>+</sup>) and Th1 cells (CD3<sup>+</sup> CD4<sup>+</sup> CXCR3<sup>+</sup> CCR4<sup>-</sup> CCR6<sup>-</sup>) in CD4<sup>+</sup> T cells in the duodenal mucosa of treated HIV-1-infected (n=11) and uninfected individuals (n=19 for Th17, n=20 for Th1 cells). Percentage of cells were determined by flow cytometry. **B.** Frequency of CXCR3<sup>+</sup> in CD8<sup>+</sup> T cells in the duodenal mucosa of treated HIV-1-infected (n=11) and uninfected individuals (n=20). Percentage of cells were determined by flow cytometry. **C.** Absolute numbers of CXCR3<sup>+</sup> cells per unit surface area in treated HIV-1-infected (n=11) and uninfected individuals (n=10). Quantification was performed by immunohistochemistry using NIS-element (Nikon). **D.** Preferential localization of CXCR3<sup>+</sup> cells in the *lamina propria* of the duodenal mucosa. Representative treated HIV-1-infected and uninfected individuals are shown. CXCR3<sup>+</sup> cells (brown) were stained by immunohistochemistry. Original magnification × 400. Groups were compared with the Wilcoxon's rank-sum test. Median bars are shown.

Figure 2. Correlations between the frequencies of Th1 in CD4<sup>+</sup> and CXCR3<sup>+</sup> in CD8<sup>+</sup> T cells and CCL20 and CCL25 expression in the duodenal mucosa.

**A.** Correlation between the frequency of Th1 in CD4<sup>+</sup> T cells and CCL20 mRNA expression (n=11 treated HIV-1-infected and n=16 uninfected individuals). **B.** Correlation between the frequency of Th1 in CD4<sup>+</sup> T cells and CCL25 mRNA expression (n=10 treated HIV-1-infected and n=9 uninfected individuals). **C.** Correlation between the frequency of CXCR3<sup>+</sup> in CD8<sup>+</sup> T cells and CCL20 mRNA expression (n=11 treated HIV-1-infected and n=16 uninfected individuals). **D.** Correlation between

the frequency of CXCR3<sup>+</sup> in CD8<sup>+</sup> T cells and CCL25 mRNA expression (n=10 treated HIV-1-infected and n=8 uninfected individuals). Th1 in CD4<sup>+</sup> and CXCR3<sup>+</sup> in CD8<sup>+</sup> T cell frequencies were assessed by flow cytometry; CCL20 and CCL25 mRNA was quantified by qRT-PCR in epithelial cells isolated from biopsies of the duodenal mucosa. Spearman's rank correlation was performed.

A.U., arbitrary unit. Uninfected individuals, white symbols; ART-treated HIV-1-infected individuals, gray symbols.

Figure 3. Functional impact of Th1- and Th17-type cytokines on CCL20 and CCL25 expression by enterocytes.

A. Effect of Th1-type cytokines IFN-γ (left panel), IL-2 (center panel), and TNF-α (right panel) on CCL20 and CCL25 expression by enterocytes. **B.** Effect of the Th17 cytokine IL-17A on CCL20 and CCL25 expression by enterocytes. **C.** Effect of inflammasome cytokines IL-18 (left panel) and IL-1β (right panel) on CCL20 and CCL25 expression by enterocytes. Monolayers of differentiated human primary enterocytes on transwell inserts were stimulated by the different cytokines at 0.5, 5, or 50 ng/mL. CCL20 and CCL25 mRNA was quantified in the enterocytes by qRT-PCR and expressed as fold-change compared to unstimulated enterocytes. **D.** Production of CCL20 protein by enterocytes at baseline and following cytokine stimulation. CCL20 was quantified in the bottom chamber by ELISA. Concentrations below the limit of detection (LOD) were assigned a value that was half of the LOD (LOD/2=3.9 pg/mL). Presented data were obtained from at least three independent experiments performed with different donors. Paired Wilcoxon's test was used; chemokine expression upon stimulation was compared to unstimulated condition in all panels; \*, P<0.05; \*\*\*, P<0.01.

A.U., arbitrary unit. Means and SEM are shown.

Figure 4. Impact of the interactions between Th1 or Th17 cells and enterocytes on CCL20 and CCL25 expression.

**A.** CCL20 and CCL25 fold-change expression in Th1:IEC relatively to Th17:IEC coculture. Enterocytes were cocultured with FACS-sorted activated Th1 or Th17 cells, added in the bottom chamber for 15 hours. CCL20 and CCL25 mRNA were quantified in the enterocytes by qRT-PCR. **B.** Production of CCL20 protein by enterocytes in Th1:IEC and Th17:IEC cocultures. CCL20 was quantified in the bottom chamber by ELISA. Impact of antagonizing IFN-γ (by an anti-IFNγR1 mAb) or IL-18 (by IL-18BP) biological activity on CCL25 (**C**) and CCL20 (**D**) expression in Th1:IEC relatively to Th17:IEC coculture. CCL20 and CCL25 mRNA were quantified in the enterocytes by qRT-PCR. Presented data were obtained from at least six independent experiments performed with different donors. Paired Wilcoxon's test was used; \*, *P*<0.05.

A.U., arbitrary unit; IEC, intestine epithelial cells. Means and SEM are shown.

Figure 5. IFN- $\gamma$  and IL-18 synergy between Th1 cells and enterocytes.

Effect of IFN-γ on IL-18 (A) and IL-18RAP (B) expression by enterocytes. Monolayers of differentiated human primary enterocytes on transwell inserts were stimulated at 0.5, 5, or 50 ng/mL of IFN-γ. IL-18 and IL-18RAP mRNA were quantified in the enterocytes by Luminex and expressed as fold-change compared to unstimulated enterocytes. C. Expression of Caspase-1 in Th1:IEC and Th17:IEC cocultures. Enterocytes were cocultured with FACS-sorted activated Th1 or Th17 cells, added in the bottom chamber for 15 hours. Caspase-1 mRNA was quantified in the enterocytes by Luminex and expressed as fold-change compared to unstimulated enterocytes. D. Production of IFN-γ by Th1 cells in the absence or presence of IL-18. FACS-sorted Th1 cells were cultured with or without IL-18 (10 ng/mL) for 15 hours. IFN-γ was quantified in the supernatant by ELISA. Presented data were obtained from at least six independent experiments performed with different donors. Paired Wilcoxon's test was used; IL-18 and IL-18RAP expression upon stimulation was compared to

unstimulated condition (panels A and B);\*, P<0.05.

A.U., arbitrary unit; IEC, intestine epithelial cells. Means and SEM are shown.

Figure 6. Functional impact of IFN-y and Th1 or Th17 cells on CXCL9, CXCL10, and CXCL11

expression by enterocytes.

A. Effect of IFN-y on CXCL9, CXCL10, and CXCL11 mRNA expression (left panel) and chemokine production (right panel). Monolayers of differentiated human primary enterocytes on transwell inserts were stimulated by IFN-y at 0.5, 5, or 50 ng/mL. CXCL9, CXCL10, and CXCL11 mRNA were quantified in the enterocytes by Luminex and expressed as fold-change compared to unstimulated enterocytes. CXCL9, CXCL10, and CXCL11 chemokines were quantified in the bottom chamber by ELISA. B. CXCL9, CXCL10, and CXCL11 fold-change expression in Th1:IEC relatively to Th17:IEC coculture. Enterocytes were cocultured with FACS-sorted activated Th1 or Th17 cells, added in the bottom chamber for 15 hours. CXCL9, CXCL10, and CXCL11 mRNA were quantified in the enterocytes by Luminex. C. CXCL9, CXCL10, and CXCL11 chemokine production in Th1:IEC and Th17:IEC cocultures. CXCL9, CXCL10, and CXCL11 chemokines were quantified in the supernantant collected from the bottom chamber by ELISA. D. Impact of antagonizing IFN-y (by an anti-IFNyR1 mAb) biological activity on CXCL9, CXCL10, and CXCL11 expression in Th1:IEC relative to Th17:IEC coculture. CXCL9, CXCL10, and CXCL11 mRNA were quantified in the enterocytes by Luminex. Presented data were obtained from at least six independent experiments performed with different donors. A.U., arbitrary unit; IEC, intestine epithelial cells. Paired Wilcoxon's test was used; chemokine expression upon stimulation was compared to unstimulated condition (panels A and B); \*, P<0.05; \*\*, P<0.01.

Means and SEM are shown.

# Figure 7. Chemotaxis of Th1 and Th17 cells in response to Th cells/IEC microenvironment.

Percentage of Th1 and Th17 cells migrating in response to a conditioned medium from Th1:IEC ( $\bf A$ ) or Th17:IEC ( $\bf B$ ) cocultures or a control medium from unstimulated enterocytes. The number of cells migrating through the 5  $\mu$ m-pore membrane in 15 hours was counted. Th1 and Th17 cell chemotaxis was antagonized by anti-CXCL9/10/11 Ab or an anti-CCL20 mAb, respectively. Experiments were repeated three times with different donors.

Paired Wilcoxon's test was used; \*, P<0.05.

IEC, intestine epithelial cells. Means and SEM are shown.

Figure 1




Figure 2




Figure 3




Figure 4







Figure 5










Figure 6




Figure 7

